Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Acquisitions & Divestments (2024 - 2025)

SAB Biotherapeutics (SABS) has disclosed Change in Acquisitions & Divestments for 2 consecutive years, with $11.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments rose 5.38% year-over-year to $11.3 million, compared with a TTM value of $21.3 million through Dec 2025, changed N/A, and an annual FY2025 reading of $21.3 million, down 17.66% over the prior year.
  • Change in Acquisitions & Divestments was $11.3 million for Q4 2025 at SAB Biotherapeutics, up from $5.2 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $11.3 million in Q4 2025 and bottomed at $3.8 million in Q3 2024.